Metsera (NASDAQ:MTSR) Trading 7.4% Higher – Here’s What Happened

Shares of Metsera, Inc. (NASDAQ:MTSR) were up 7.4% on Tuesday . The stock traded as high as $20.00 and last traded at $19.53. Approximately 178,578 shares traded hands during mid-day trading, a decline of 77% from the average daily volume of 780,994 shares. The stock had previously closed at $18.18.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on MTSR. Evercore ISI initiated coverage on Metsera in a report on Tuesday, February 25th. They set an “outperform” rating for the company. Cantor Fitzgerald began coverage on Metsera in a report on Tuesday, February 25th. They issued an “overweight” rating for the company. Bank of America began coverage on shares of Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $38.00 price target on the stock. Finally, Guggenheim assumed coverage on shares of Metsera in a research note on Tuesday, February 25th. They set a “buy” rating and a $56.00 target price on the stock.

Metsera Price Performance

The company has a 50-day simple moving average of $25.58.

Metsera (NASDAQ:MTSR) last posted its earnings results on Wednesday, March 26th. The company reported ($3.52) EPS for the quarter.

About Metsera

Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.